WO2009004995A1 - 生理活性物質を定着および発現させる方法 - Google Patents
生理活性物質を定着および発現させる方法 Download PDFInfo
- Publication number
- WO2009004995A1 WO2009004995A1 PCT/JP2008/061709 JP2008061709W WO2009004995A1 WO 2009004995 A1 WO2009004995 A1 WO 2009004995A1 JP 2008061709 W JP2008061709 W JP 2008061709W WO 2009004995 A1 WO2009004995 A1 WO 2009004995A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- active substance
- physiologically active
- fixing
- administered
- expressing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dispersion Chemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Nutrition Science (AREA)
Abstract
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/666,983 US20100329993A1 (en) | 2007-06-29 | 2008-06-27 | Method of fixing and expressing physiologically active substance |
EP21163980.2A EP3895737A1 (en) | 2007-06-29 | 2008-06-27 | Method of fixing and expressing physiologically active substance |
EP08790674A EP2172226A4 (en) | 2007-06-29 | 2008-06-27 | METHOD FOR FIXING AND EXPRESSING A PHYSIOLOGICALLY ACTIVE SUBSTANCE |
EP15201508.7A EP3034095B1 (en) | 2007-06-29 | 2008-06-27 | Method of fixing and expressing physiologically active substance |
JP2009521604A JP5547964B2 (ja) | 2007-06-29 | 2008-06-27 | 生理活性物質を定着および発現させる方法 |
EP18188952.8A EP3456357A1 (en) | 2007-06-29 | 2008-06-27 | Method of fixing and expressing physiologically active substance |
EP20170385.7A EP3711755A1 (en) | 2007-06-29 | 2008-06-27 | Method of fixing and expressing physiologically active substance |
US14/158,607 US20140135379A1 (en) | 2007-06-29 | 2014-01-17 | Method of fixing and expressing physiologically active substance |
US15/241,830 US20160355818A1 (en) | 2007-06-29 | 2016-08-19 | Method of fixing and expressing physiologically active substance |
US16/269,359 US10689650B2 (en) | 2007-06-29 | 2019-02-06 | Method of fixing and expressing physiologically active substance |
US16/869,812 US11485974B2 (en) | 2007-06-29 | 2020-05-08 | Method of fixing and expressing physiologically active substance |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007171361 | 2007-06-29 | ||
JP2007-171361 | 2007-06-29 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/666,983 A-371-Of-International US20100329993A1 (en) | 2007-06-29 | 2008-06-27 | Method of fixing and expressing physiologically active substance |
US14/158,607 Continuation US20140135379A1 (en) | 2007-06-29 | 2014-01-17 | Method of fixing and expressing physiologically active substance |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009004995A1 true WO2009004995A1 (ja) | 2009-01-08 |
Family
ID=40226041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/061709 WO2009004995A1 (ja) | 2007-06-29 | 2008-06-27 | 生理活性物質を定着および発現させる方法 |
Country Status (5)
Country | Link |
---|---|
US (5) | US20100329993A1 (ja) |
EP (7) | EP2638917A1 (ja) |
JP (1) | JP5547964B2 (ja) |
ES (1) | ES2685636T3 (ja) |
WO (1) | WO2009004995A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014013535A1 (ja) * | 2012-07-17 | 2014-01-23 | 株式会社ステリック再生医科学研究所 | 粘膜治癒促進剤 |
JP2015515886A (ja) * | 2012-05-01 | 2015-06-04 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 経皮挿入するための先端装填型マイクロニードルアレイ |
WO2018105708A1 (ja) | 2016-12-07 | 2018-06-14 | 株式会社ステリック再生医科学研究所 | 慢性疾患の治療及び予防用医薬組成物 |
US10441768B2 (en) | 2015-03-18 | 2019-10-15 | University of Pittsburgh—of the Commonwealth System of Higher Education | Bioactive components conjugated to substrates of microneedle arrays |
US10646579B2 (en) | 2015-11-04 | 2020-05-12 | Tme Therapeutics Inc. | Complex comprising RNAi molecule and N-acetylated chitosan |
EP3673910A1 (en) * | 2007-12-27 | 2020-07-01 | Stelic Institute Of Regenerative Medicine, Stelic Institute & Co. | Sugar chain-related gene and use thereof |
US11684763B2 (en) | 2015-10-16 | 2023-06-27 | University of Pittsburgh—of the Commonwealth System of Higher Education | Multi-component bio-active drug delivery and controlled release to the skin by microneedle array devices |
US11744889B2 (en) | 2016-01-05 | 2023-09-05 | University of Pittsburgh—of the Commonwealth System of Higher Education | Skin microenvironment targeted delivery for promoting immune and other responses |
US11744927B2 (en) | 2009-10-23 | 2023-09-05 | University of Pittsburgh—of the Commonwealth System of Higher Education | Dissolvable microneedle arrays for transdermal delivery to human skin |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180193003A1 (en) | 2016-12-07 | 2018-07-12 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
CA3054159A1 (en) | 2017-03-30 | 2018-10-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0454352B2 (ja) | 1983-01-18 | 1992-08-31 | Sanyo Electric Co | |
JPH09505575A (ja) | 1993-11-23 | 1997-06-03 | ローン−プーラン・ロレ・ソシエテ・アノニム | イン・ビボでの治療性生産物の生産のための組成物 |
JP2003516365A (ja) | 1999-12-08 | 2003-05-13 | フアルマコンセプツ・エイビー | 核酸送達系 |
JP2005503199A (ja) | 2001-06-14 | 2005-02-03 | クック インコーポレーテッド | 脈管内フィルター |
WO2005063293A1 (ja) * | 2003-12-26 | 2005-07-14 | Masatoshi Hagiwara | Sr蛋白質のリン酸化制御方法、および、sr蛋白質の活性制御剤を有効成分とする抗ウイルス剤 |
JP2005538943A (ja) | 2002-05-03 | 2005-12-22 | エフエムシー バイオポリマー エイエス | 非ウイルス性遺伝子送達システム |
JP2007502616A (ja) * | 2003-08-18 | 2007-02-15 | アイシス ファーマシューティカルズ インコーポレイテッド | ジアシルグリセロールアシルトランスフェラーゼ2発現の調節 |
JP2007119498A (ja) | 2001-11-05 | 2007-05-17 | Seikagaku Kogyo Co Ltd | 上皮膨隆高の維持用組成物 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4054352A (en) * | 1975-08-25 | 1977-10-18 | Rudin Marvin B | Electrical power take-off unit for cigarette lighter socket of vehicle |
US5695998A (en) | 1995-02-10 | 1997-12-09 | Purdue Research Foundation | Submucosa as a growth substrate for islet cells |
US6448081B1 (en) * | 2001-05-07 | 2002-09-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of interleukin 12 p40 subunit expression |
JP4339978B2 (ja) * | 1999-01-26 | 2009-10-07 | インターベツト・インターナシヨナル・ベー・ベー | ワクチンの製造のための細菌の使用 |
FR2797274B1 (fr) | 1999-08-02 | 2003-09-05 | Agronomique Inst Nat Rech | Gene mutant de la famille gras, et plantes a developpement reduit comprenant ledit gene |
DE60133284T2 (de) * | 2000-06-06 | 2009-03-26 | Lequio Pharma Co.Ltd., Naha | Medizinisches kombinationspräparat zur behandlung von verletztem abnormem gewebe |
HU230458B1 (hu) * | 2000-12-01 | 2016-07-28 | Europäisches Laboratorium für Molekularbiologie (EMBL) | Az RNS interferenciát közvetítő kis RNS molekulák |
EP1386004A4 (en) * | 2001-04-05 | 2005-02-16 | Ribozyme Pharm Inc | MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID |
US7008626B2 (en) * | 2001-11-05 | 2006-03-07 | Seikagaku Corporation | Medical composition for protuberance of epithelium |
US20050106729A1 (en) * | 2002-05-03 | 2005-05-19 | Mark Irvin Rosenblatt | Gene transfer methods and compositions |
EP1541580B1 (en) * | 2002-07-10 | 2013-02-27 | Seikagaku Corporation | Sulfotransferase inhibitors |
US7148342B2 (en) * | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
DE602004015064D1 (de) * | 2003-01-06 | 2008-08-28 | Wyeth Corp | Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs |
EP1624858B1 (en) * | 2003-04-09 | 2018-06-06 | Rutgers, the State University of New Jersey | Novel encochleation methods |
AU2005209909B8 (en) * | 2004-02-03 | 2009-01-15 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
US20050272682A1 (en) * | 2004-03-22 | 2005-12-08 | Evers Bernard M | SiRNA targeting PI3K signal transduction pathway and siRNA-based therapy |
US7972295B2 (en) * | 2005-03-11 | 2011-07-05 | Boston Scientific Scimed, Inc. | Apparatus and methods for delivering a bolus of therapeutic material |
WO2007049361A1 (ja) * | 2005-10-27 | 2007-05-03 | Stelic Corp. | 肝線維化抑制剤 |
JP5281411B2 (ja) * | 2005-12-23 | 2013-09-04 | ヴィセラ・バイオメディカル・リミテッド | 胃から食道への逆流の治療に適した医療器具 |
CA2644513A1 (en) * | 2006-03-03 | 2007-09-07 | London Health Sciences Centre Research Inc. | Preventing il-2 mediated inflammation in epithelial cells |
KR20080102196A (ko) | 2006-03-15 | 2008-11-24 | 도요다 지도샤 가부시끼가이샤 | 복수개의 육각셀로 구성된 허니콤 구조체 |
AU2007229161B2 (en) * | 2006-03-23 | 2012-07-12 | Roche Innovation Center Copenhagen A/S | Small internally segmented interfering RNA |
CN101448848B (zh) * | 2006-03-27 | 2013-12-04 | 全球免疫股份有限公司 | Ras突变及其相关组合物和方法 |
WO2007116395A2 (en) * | 2006-04-10 | 2007-10-18 | Ester Neurosciences Ltd. | Antisense oligonucleotides against acetylcholinesterase for treating inflammatory diseases |
WO2007130604A2 (en) * | 2006-05-04 | 2007-11-15 | Baylor Research Institute | Anti-tumor activity of an oncolytic adenovirus-delivered oncogene sirna |
JP4147264B2 (ja) * | 2006-09-08 | 2008-09-10 | 株式会社ステリック再生医科学研究所 | 神経線維性変性抑制剤 |
CN103656644A (zh) * | 2007-12-27 | 2014-03-26 | 斯特里克再生医学学院,斯特里克学院事务所 | 糖链相关基因及其利用 |
JP2012515603A (ja) * | 2009-01-27 | 2012-07-12 | サイレンシード リミテッド | インプラント送達の方法とシステム |
-
2008
- 2008-06-27 EP EP20130001163 patent/EP2638917A1/en not_active Withdrawn
- 2008-06-27 EP EP15201508.7A patent/EP3034095B1/en active Active
- 2008-06-27 EP EP18188952.8A patent/EP3456357A1/en not_active Withdrawn
- 2008-06-27 WO PCT/JP2008/061709 patent/WO2009004995A1/ja active Application Filing
- 2008-06-27 EP EP20170385.7A patent/EP3711755A1/en not_active Withdrawn
- 2008-06-27 EP EP17180709.2A patent/EP3284486A1/en not_active Withdrawn
- 2008-06-27 EP EP21163980.2A patent/EP3895737A1/en active Pending
- 2008-06-27 ES ES15201508.7T patent/ES2685636T3/es active Active
- 2008-06-27 EP EP08790674A patent/EP2172226A4/en not_active Withdrawn
- 2008-06-27 JP JP2009521604A patent/JP5547964B2/ja active Active
- 2008-06-27 US US12/666,983 patent/US20100329993A1/en not_active Abandoned
-
2014
- 2014-01-17 US US14/158,607 patent/US20140135379A1/en not_active Abandoned
-
2016
- 2016-08-19 US US15/241,830 patent/US20160355818A1/en not_active Abandoned
-
2019
- 2019-02-06 US US16/269,359 patent/US10689650B2/en active Active
-
2020
- 2020-05-08 US US16/869,812 patent/US11485974B2/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0454352B2 (ja) | 1983-01-18 | 1992-08-31 | Sanyo Electric Co | |
JPH09505575A (ja) | 1993-11-23 | 1997-06-03 | ローン−プーラン・ロレ・ソシエテ・アノニム | イン・ビボでの治療性生産物の生産のための組成物 |
JP2003516365A (ja) | 1999-12-08 | 2003-05-13 | フアルマコンセプツ・エイビー | 核酸送達系 |
JP2005503199A (ja) | 2001-06-14 | 2005-02-03 | クック インコーポレーテッド | 脈管内フィルター |
JP2007119498A (ja) | 2001-11-05 | 2007-05-17 | Seikagaku Kogyo Co Ltd | 上皮膨隆高の維持用組成物 |
JP2005538943A (ja) | 2002-05-03 | 2005-12-22 | エフエムシー バイオポリマー エイエス | 非ウイルス性遺伝子送達システム |
JP2007502616A (ja) * | 2003-08-18 | 2007-02-15 | アイシス ファーマシューティカルズ インコーポレイテッド | ジアシルグリセロールアシルトランスフェラーゼ2発現の調節 |
WO2005063293A1 (ja) * | 2003-12-26 | 2005-07-14 | Masatoshi Hagiwara | Sr蛋白質のリン酸化制御方法、および、sr蛋白質の活性制御剤を有効成分とする抗ウイルス剤 |
Non-Patent Citations (26)
Title |
---|
AKAMO Y. ET AL.: "Chemotherapy targeting regional lymph nodes by gastric submucosal injection of liposomal adriamycin in patients with gastric carcinoma", JPN. J. CANCER RES., vol. 85, no. 6, 1994, pages 652 - 658, XP008129076 * |
BERNSTEIN, E., NATURE, vol. 409, pages 363 - 366 |
BUZAYAN, J.M., NATURE, vol. 323, 1986, pages 349 |
ELBASHIR SM. ET AL., NATURE, vol. 411, 2001, pages 494 - 498 |
ENSHOSEI CHO SHIKKAN NO KAKKITEKI CHIRYOHO NI KANSURU RINSHO KENKYU HEISEI 17 NENDO SOKATSU.BUNTAN KENKYU HOKOKUSHO, 2006 * |
FIRE, A. ET AL., NATURE, vol. 391, 1998, pages 806 - 811 |
HAMMOND, S.M. ET AL., SCIENCE, vol. 293, 2001, pages 1146 - 1150 |
HARIMOTO K.: "Hi-Virus.Vector ni yoru Boko eno IN VIVO Idenshi Donyuho", THE JOURNAL OF THE OSAKA CITY MEDICAL CENTER, vol. 48, no. 3-4, 1999, pages 435 - 442, XP008129075 * |
HIRASHIMA; INOUE: "New Courses in Experimental Biochemistry", 1993, THE JAPANESE BIOCHEMICAL SOCIETY, article "Idenshi no Fukusei to Hatsugen", pages: 319 - 347 |
KAWAUCHI Y. ET AL.: "Naishikyo o Mochiita Rat DDS Choen ni Taisuru HGF Idenshi Donyu no Kokoromi", DIGESTIVE ORGAN AND IMMUNOLOGY, no. 43, 2006, pages 98 - 101 * |
KIHARA M, GUT., vol. 52, 2003, pages 713 - 9 |
KIKUCHI, Y.; KAGAKU TO SEIBUTSU, CHEMISTRY AND BIOLOGY, vol. 30, 1992, pages 112 |
KIKUCHI, Y.; SASAKI, N., NUCL ACIDS RES., vol. 19, 1991, pages 6751 |
KOIZUMI, M. ET AL., FEBS LETT., vol. 239, 1988, pages 285 |
KOIZUMI, M. ET AL., NUCL. ACIDS RES., vol. 17, 1989, pages 7059 |
KOIZUMI, M.; OTSUKA, E., PROTEIN, NUCLEIC ACID, AND ENZYME, vol. 35, 1990, pages 2191 |
OKAYASU I; HATAKEYAMA S; OHKUSA T; INAGAKI Y; NAKAYA R: "A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice", GASTROENTEROLOGY, vol. 98, 1990, pages 694 - 702 |
PUCILOWSKA JB ET AL., AM J PHYSIOL GASTROENTEROL LIVER PHYSIOL., vol. 279, 2000, pages G653 - G659 |
ROSIE Z ET AL., ANALYTICAL BIOCHEM., vol. 304, 2002, pages 19 - 25 |
SASAKI N, J INFLAMM., vol. 2, 2005, pages 13 |
See also references of EP2172226A4 |
SUZUKI K.: "Enshosei Cho Shikkan ni Taisuru HGF Oyobi HGF Idenshi o Mochiita Nenmaku Saisei Ryoho no Kaihatsu", ENSHOSEI CHO SHIKKAN NO KAKKITEKI CHIRYOHO NI KANSURU RINSHO KENKYU HEISEI 17 NENDO SOKATSU.BUNTAN KENKYU HOKOKUSHO, 2006, pages 31 - 34 * |
SUZUKI K.: "Enshosei Cho Shikkan ni Taisuru Yakuzai no Naishikyoteki Shokakan Nenmakuka Chunyu Ryoho no Kaihatsu", ENSHOSEI CHOSHIKKAN NA KAKKITEKI CHIRYOHO NI KANSURU RINSHO KENKYU HEISEI 18 NENDO SOKATSU.BUNTAN KENKYU HOKOKUSHO, March 2007 (2007-03-01), pages 16 - 19 * |
TAKEHARA T. ET AL.: "In vivo gene transfer and expression in rat stomach by submucosal injection of plasmid DNA", HUMAN GENE THERAPY, vol. 7, no. 5, 1996, pages 589 - 593, XP008129050 * |
TIAN XH ET AL., HEPATOBILIARY PANCREAT DIS INT., vol. 4, 2005, pages 524 |
ZAMORE PD. ET AL., CELL, vol. 101, 2000, pages 25 - 33 |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3673910A1 (en) * | 2007-12-27 | 2020-07-01 | Stelic Institute Of Regenerative Medicine, Stelic Institute & Co. | Sugar chain-related gene and use thereof |
US11744927B2 (en) | 2009-10-23 | 2023-09-05 | University of Pittsburgh—of the Commonwealth System of Higher Education | Dissolvable microneedle arrays for transdermal delivery to human skin |
JP2015515886A (ja) * | 2012-05-01 | 2015-06-04 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 経皮挿入するための先端装填型マイクロニードルアレイ |
US9944019B2 (en) | 2012-05-01 | 2018-04-17 | University of Pittsburgh—of the Commonwealth System of Higher Education | Tip-loaded microneedle arrays for transdermal insertion |
JPWO2014013535A1 (ja) * | 2012-07-17 | 2016-06-23 | 株式会社ステリック再生医科学研究所 | 粘膜治癒促進剤 |
WO2014013535A1 (ja) * | 2012-07-17 | 2014-01-23 | 株式会社ステリック再生医科学研究所 | 粘膜治癒促進剤 |
EP3693462A1 (en) * | 2012-07-17 | 2020-08-12 | Stelic Institute&Co. | Mucosal healing promoter |
EP3878962A1 (en) * | 2012-07-17 | 2021-09-15 | Stelic Institute & Co. | Mucosal healing promoter |
US11672964B2 (en) | 2015-03-18 | 2023-06-13 | University of Pittsburgh—of the Commonwealth System of Higher Education | Bioactive components conjugated to substrates of microneedle arrays |
US10441768B2 (en) | 2015-03-18 | 2019-10-15 | University of Pittsburgh—of the Commonwealth System of Higher Education | Bioactive components conjugated to substrates of microneedle arrays |
US10737083B2 (en) | 2015-03-18 | 2020-08-11 | University of Pittsburgh—of the Commonwealth System of Higher Education | Bioactive components conjugated to dissolvable substrates of microneedle arrays |
US11684763B2 (en) | 2015-10-16 | 2023-06-27 | University of Pittsburgh—of the Commonwealth System of Higher Education | Multi-component bio-active drug delivery and controlled release to the skin by microneedle array devices |
US10646579B2 (en) | 2015-11-04 | 2020-05-12 | Tme Therapeutics Inc. | Complex comprising RNAi molecule and N-acetylated chitosan |
US11744889B2 (en) | 2016-01-05 | 2023-09-05 | University of Pittsburgh—of the Commonwealth System of Higher Education | Skin microenvironment targeted delivery for promoting immune and other responses |
WO2018105708A1 (ja) | 2016-12-07 | 2018-06-14 | 株式会社ステリック再生医科学研究所 | 慢性疾患の治療及び予防用医薬組成物 |
US11911409B2 (en) | 2016-12-07 | 2024-02-27 | Stelic Institute & Co., Inc. | Pharmaceutical composition for treatment and prevention of chronic disease |
Also Published As
Publication number | Publication date |
---|---|
EP3456357A1 (en) | 2019-03-20 |
US20100329993A1 (en) | 2010-12-30 |
EP2172226A1 (en) | 2010-04-07 |
EP3284486A1 (en) | 2018-02-21 |
EP3895737A1 (en) | 2021-10-20 |
US20190153447A1 (en) | 2019-05-23 |
US10689650B2 (en) | 2020-06-23 |
EP3711755A1 (en) | 2020-09-23 |
JPWO2009004995A1 (ja) | 2010-08-26 |
EP2638917A1 (en) | 2013-09-18 |
US11485974B2 (en) | 2022-11-01 |
US20140135379A1 (en) | 2014-05-15 |
EP2172226A4 (en) | 2010-06-30 |
US20210040478A1 (en) | 2021-02-11 |
EP3034095B1 (en) | 2018-08-08 |
JP5547964B2 (ja) | 2014-07-16 |
US20160355818A1 (en) | 2016-12-08 |
ES2685636T3 (es) | 2018-10-10 |
EP3034095A1 (en) | 2016-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009004995A1 (ja) | 生理活性物質を定着および発現させる方法 | |
CY1119616T1 (el) | Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα | |
NO20073456L (no) | Omega-3 fettsyrer og dyslipidemisk middel for lipidbehandling | |
NZ606825A (en) | Methods and compositions for treating complement-associated disorders | |
MX2009013574A (es) | Formas de dosificacion solidas o semisolidas de liberacion modificada. | |
WO2007009539A3 (en) | Use of inhibitors of histone deacetylases in combination with nsaid for the therapy of cancer and/or inflammatory diseases | |
WO2010009116A3 (en) | Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents | |
EA200970360A1 (ru) | Омега-3 жирные кислоты и средство для лечения дислипидемии для снижения уровней аро-в | |
TW200640497A (en) | Pharmaceutical formulations and methods of use | |
WO2009120484A3 (en) | Pharmaceutical gels and methods for delivering therapeutic agents to a site beneath the skin | |
WO2010006219A3 (en) | Use of scaffold comprising fibrin for delivery of stem cells | |
BR112013005673A2 (pt) | uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes | |
WO2007012022A3 (en) | Unit dose form with ibuprofen-famotidine admixture | |
MX2009011900A (es) | Curacion de herida diabetica. | |
WO2009022338A3 (en) | Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications | |
TW200833367A (en) | Pharmaceutical compositions and method for treating inflammation in cattle and other animals | |
WO2008109119A3 (en) | Wnt compositions and methods of use thereof | |
EP2236129A3 (en) | Liposomal ALA Pharmaceutical and Cosmeceutical Compositions and Methods of Treatment | |
WO2012019188A3 (en) | Methods and compositions for the inhibition of fructokinase | |
CA2899775C (en) | Compositions and methods for pain relief without numbness | |
NZ591408A (en) | Paracetamol and Calcium carbonate composition | |
WO2009129510A3 (en) | Sulindac formulations in a biodegradable material | |
WO2007038641A3 (en) | Methods and therapies for treating inflammatory conditions with exposed collagen | |
AR048806A1 (es) | Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio | |
WO2004100893A3 (en) | Methods for treatment of inflammatory diseases using ct-3 or analogs thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08790674 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2009521604 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008790674 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12666983 Country of ref document: US |